New Tool to Study Critical Protein Interaction in Cancer Research
News Jul 03, 2014
A recent study by scientists from the Agency for Science, Technology and Research (A*STAR) is the first to report on the use of fluorescent molecular rotors for cancer drug development. The study was published on 30 April as the cover article in the Journal of The American Chemical Society (JACS).
On the cellular level, cancer is the uncontrolled growth of cells containing damaged or mutated DNA which could result in tumours. p53 is a ‘tumour suppressor protein’ because it functions as the body’s defence against cancer by binding to regulatory sites on the genome and trigger repair mechanisms to the DNA. Alternatively, p53 is also known to initiate a process of apoptosis or programmed cell death.
MDM2 protein is a negative regulator of p53. This means that a high level of MDM2 inhibits the activity of p53 by binding to it and breaking it down; on the other hand, when mutated or damaged DNA is detected, the level of MDM2 falls and allows p53 to initiate DNA repair. The breakdown of the regulatory abilities of MDM2 and p53 will lead to tumours. For instance, an overexpression of MDM2 has been observed in soft tissue sarcomas, gliomas, lymphomas and breast cancer. The study of MDM2-p53 interaction is, therefore, important in cancer research.
In this study, A*STAR scientists used fluorescent molecular rotors to study protein-protein interactions involving p53 and MDM2 in cells. They found that the fluorescent molecular rotor fluoresces or “lights up” when it is coupled with a short peptide fragment of the MDM2.
Armed with this finding, the scientists screened a library of small molecule fragments for candidates that may potentially disrupt p53-MDM2 binding. They detected a total of 15 hits – eight were validated by an existing method known as fluorescence polarisation and found extra seven which were missed out.
Dr Teo Yin Nah, Research Fellow at A*STAR’s Molecular Engineering Laboratory, said: “Researchers have used molecular rotors as viscosity sensor probes in live cells. This is the first time we have proved that molecular rotors can be used in a different way to understanding molecular interactions that causes cancer. Scientists now have another tool in their arsenal to further our understanding of the MDM2-p53 interaction.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018